BACKGROUND: Ligation of the platelet-specific collagen receptor, GPVI/FcRγ, causes rapid, transient disulfide-dependent homodimerization, and the production of intracellular reactive oxygen species (ROS) generated by the NADPH oxidase, linked to GPVI via TRAF4. OBJECTIVES: The aim of this study was to evaluate the role of early signaling events in ROS generation following engagement of either GPVI/FcRγ or a second immunoreceptor tyrosine-based activation motif (ITAM)-containing receptor on platelets, FcγRIIa. METHODS AND RESULTS: Using an H(2) DCF-DA-based flow cytometric assay to measure intracellular ROS, we show that treatment of platelets with either the GPVI agonists, collagen-related peptide (CRP) or convulxin (Cvx), or the FcγRIIa agonist 14A2, increased intraplatelet ROS; other platelet agonists such as ADP and TRAP did not. Basal ROS in platelet-rich plasma from 14 healthy donors displayed little inter-individual variability. CRP, Cvx or 14A2 induced an initial burst of ROS within 2 min followed by additional ROS reaching a plateau after 15-20 min. The Syk inhibitor BAY61-3606, which blocks ITAM-dependent signaling, had no effect on the initial ROS burst, but completely inhibited the second phase. CONCLUSIONS: Together, these results show for the first time that ROS generation downstream of GPVI or FcγRIIa consists of two distinct phases: an initial Syk-independent burst followed by additional Syk-dependent generation.
BACKGROUND: Ligation of the platelet-specific collagen receptor, GPVI/FcRγ, causes rapid, transient disulfide-dependent homodimerization, and the production of intracellular reactive oxygen species (ROS) generated by the NADPH oxidase, linked to GPVI via TRAF4. OBJECTIVES: The aim of this study was to evaluate the role of early signaling events in ROS generation following engagement of either GPVI/FcRγ or a second immunoreceptor tyrosine-based activation motif (ITAM)-containing receptor on platelets, FcγRIIa. METHODS AND RESULTS: Using an H(2) DCF-DA-based flow cytometric assay to measure intracellular ROS, we show that treatment of platelets with either the GPVI agonists, collagen-related peptide (CRP) or convulxin (Cvx), or the FcγRIIa agonist 14A2, increased intraplatelet ROS; other platelet agonists such as ADP and TRAP did not. Basal ROS in platelet-rich plasma from 14 healthy donors displayed little inter-individual variability. CRP, Cvx or 14A2 induced an initial burst of ROS within 2 min followed by additional ROS reaching a plateau after 15-20 min. The Syk inhibitor BAY61-3606, which blocks ITAM-dependent signaling, had no effect on the initial ROS burst, but completely inhibited the second phase. CONCLUSIONS: Together, these results show for the first time that ROS generation downstream of GPVI or FcγRIIa consists of two distinct phases: an initial Syk-independent burst followed by additional Syk-dependent generation.
Authors: Carolina D Weller; Elizabeth E Gardiner; Jane F Arthur; Melissa Southey; Robert K Andrews Journal: Int Wound J Date: 2019-03-12 Impact factor: 3.315
Authors: H Akbar; X Duan; R Piatt; S Saleem; A K Davis; N N Tandon; W Bergmeier; Y Zheng Journal: J Thromb Haemost Date: 2018-08-13 Impact factor: 5.824
Authors: Teresa C F Assumpção; Dongying Ma; Alexandra Schwarz; Karine Reiter; Jaime M Santana; John F Andersen; José M C Ribeiro; Glenn Nardone; Lee L Yu; Ivo M B Francischetti Journal: J Biol Chem Date: 2013-04-05 Impact factor: 5.157
Authors: Hyo-Jung Choo; Talib B Saafir; Laura Mkumba; Mary B Wagner; Shawn M Jobe Journal: Arterioscler Thromb Vasc Biol Date: 2012-10-18 Impact factor: 8.311
Authors: J F Arthur; Y Shen; Y Chen; J Qiao; R Ni; Y Lu; R K Andrews; E E Gardiner; J Cheng Journal: J Diabetes Res Date: 2013-06-06 Impact factor: 4.011